Literature DB >> 3308562

Macrovascular complications in relation to hyperinsulinaemia in non-insulin-dependent diabetes mellitus.

K Pyörälä1, M Uusitupa, M Laakso, O Siitonen, L Niskanen, T Rönnemaa.   

Abstract

Despite suggestive evidence from studies on experimental pathology and cell biology of the arterial wall and from clinical and epidemiological studies on non-diabetic subjects indicating that hyperinsulinaemia might be associated with an increased risk of atherosclerotic vascular disease (ASVD) information concerning the role of hyperinsulinaemia as a risk factor of ASVD in diabetic patients still is circumstantial. A few cross-sectional and still fewer prospective studies in patients with non-insulin-dependent diabetes (NIDDM), including two ongoing studies carried out by our own research group, have shown associations between hyperinsulinaemia and the occurrence of ASVD, but these data still are far from consistent and conclusive. Further studies applying combined clinical and epidemiological approach, building upon the results of experimental research concerning possible mechanisms, are needed for better clarification of the role of hyperinsulinaemia as a risk factor of ASVD in NIDDM.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308562

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  9 in total

Review 1.  Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice.

Authors:  S Vijan; D L Stevens; W H Herman; M M Funnell; C J Standiford
Journal:  J Gen Intern Med       Date:  1997-09       Impact factor: 5.128

Review 2.  Diabetes and atherosclerosis. Metabolic links.

Authors:  G Steiner
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Is insulin atherogenic?

Authors:  R J Jarrett
Journal:  Diabetologia       Date:  1988-02       Impact factor: 10.122

Review 4.  Triglycerides and disease.

Authors:  C A Seymour; C D Byrne
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

5.  Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.

Authors:  Bo Feng; Lei Xu; Hua Wang; Xinfeng Yan; Junli Xue; Fengjing Liu; Ji-Fan Hu
Journal:  Biochim Biophys Acta       Date:  2011-05-30

6.  Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study.

Authors:  A Fontbonne; E Eschwège; F Cambien; J L Richard; P Ducimetière; N Thibult; J M Warnet; J R Claude; G E Rosselin
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

7.  The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.

Authors:  A C Calkin; S Giunti; K J Sheehy; C Chew; V Boolell; Y S Rajaram; M E Cooper; K A Jandeleit-Dahm
Journal:  Diabetologia       Date:  2008-07-02       Impact factor: 10.122

8.  Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up.

Authors:  A Fontbonne; M A Charles; N Thibult; J L Richard; J R Claude; J M Warnet; G E Rosselin; E Eschwège
Journal:  Diabetologia       Date:  1991-05       Impact factor: 10.122

9.  Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol.

Authors:  Lei Xu; Yi-Ru Wang; Pei-Cheng Li; Bo Feng
Journal:  Lipids Health Dis       Date:  2016-09-19       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.